vs
雅培（CLB）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是雅培的1.7倍（$207.3M vs $121.8M），雅培净利率更高（4.2% vs -62.0%，领先66.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs -1.4%），雅培自由现金流更多（$517.0K vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs -3.4%）
雅培是一家总部位于美国伊利诺伊州阿伯特公园的跨国医疗保健企业，在全球医疗健康领域开展业务，主营诊断产品、营养健康产品、医疗器械，同时在美国境外销售医药产品，是全球知名的医疗健康提供商。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
CLB vs RARE — 直观对比
营收规模更大
RARE
是对方的1.7倍
$121.8M
营收增速更快
RARE
高出27.3%
-1.4%
净利率更高
CLB
高出66.2%
-62.0%
自由现金流更多
CLB
多$101.3M
$-100.8M
两年增速更快
RARE
近两年复合增速
-3.4%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $121.8M | $207.3M |
| 净利润 | $5.1M | $-128.6M |
| 毛利率 | — | — |
| 营业利润率 | 1.5% | -54.7% |
| 净利率 | 4.2% | -62.0% |
| 营收同比 | -1.4% | 25.9% |
| 净利润同比 | — | 3.5% |
| 每股收益（稀释后） | $0.11 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CLBRARE
| Q1 26 | $121.8M | — | ||
| Q4 25 | $138.3M | $207.3M | ||
| Q3 25 | $134.5M | $159.9M | ||
| Q2 25 | $130.2M | $166.5M | ||
| Q1 25 | $123.6M | $139.3M | ||
| Q4 24 | $129.2M | $164.6M | ||
| Q3 24 | $134.4M | $139.5M | ||
| Q2 24 | $130.6M | $147.0M |
净利润CLBRARE
| Q1 26 | $5.1M | — | ||
| Q4 25 | $4.9M | $-128.6M | ||
| Q3 25 | $14.2M | $-180.4M | ||
| Q2 25 | $10.6M | $-115.0M | ||
| Q1 25 | $-154.0K | $-151.1M | ||
| Q4 24 | $7.4M | $-133.2M | ||
| Q3 24 | $11.7M | $-133.5M | ||
| Q2 24 | $9.0M | $-131.6M |
毛利率CLBRARE
| Q1 26 | — | — | ||
| Q4 25 | 20.8% | — | ||
| Q3 25 | 22.0% | — | ||
| Q2 25 | 20.3% | — | ||
| Q1 25 | 19.5% | — | ||
| Q4 24 | 17.8% | — | ||
| Q3 24 | 20.5% | — | ||
| Q2 24 | 21.2% | — |
营业利润率CLBRARE
| Q1 26 | 1.5% | — | ||
| Q4 25 | 11.5% | -54.7% | ||
| Q3 25 | 15.6% | -106.9% | ||
| Q2 25 | 11.7% | -64.8% | ||
| Q1 25 | 3.6% | -102.6% | ||
| Q4 24 | 11.0% | -74.3% | ||
| Q3 24 | 14.7% | -94.6% | ||
| Q2 24 | 12.3% | -79.1% |
净利率CLBRARE
| Q1 26 | 4.2% | — | ||
| Q4 25 | 3.6% | -62.0% | ||
| Q3 25 | 10.6% | -112.8% | ||
| Q2 25 | 8.2% | -69.0% | ||
| Q1 25 | -0.1% | -108.5% | ||
| Q4 24 | 5.7% | -80.9% | ||
| Q3 24 | 8.7% | -95.7% | ||
| Q2 24 | 6.9% | -89.5% |
每股收益（稀释后）CLBRARE
| Q1 26 | $0.11 | — | ||
| Q4 25 | $0.11 | $-1.28 | ||
| Q3 25 | $0.30 | $-1.81 | ||
| Q2 25 | $0.22 | $-1.17 | ||
| Q1 25 | $0.00 | $-1.57 | ||
| Q4 24 | $0.15 | $-1.34 | ||
| Q3 24 | $0.25 | $-1.40 | ||
| Q2 24 | $0.19 | $-1.52 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $22.8M | $421.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $275.1M | $-80.0M |
| 总资产 | $587.7M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CLBRARE
| Q1 26 | $22.8M | — | ||
| Q4 25 | $22.7M | $421.0M | ||
| Q3 25 | $25.6M | $202.5M | ||
| Q2 25 | $31.2M | $176.3M | ||
| Q1 25 | $22.1M | $127.1M | ||
| Q4 24 | $19.2M | $174.0M | ||
| Q3 24 | $21.5M | $150.6M | ||
| Q2 24 | $17.7M | $480.7M |
总债务CLBRARE
| Q1 26 | — | — | ||
| Q4 25 | $110.3M | — | ||
| Q3 25 | $114.1M | — | ||
| Q2 25 | $124.6M | — | ||
| Q1 25 | $124.4M | — | ||
| Q4 24 | $126.1M | — | ||
| Q3 24 | $139.9M | — | ||
| Q2 24 | $147.6M | — |
股东权益CLBRARE
| Q1 26 | $275.1M | — | ||
| Q4 25 | $266.0M | $-80.0M | ||
| Q3 25 | $271.3M | $9.2M | ||
| Q2 25 | $261.3M | $151.3M | ||
| Q1 25 | $253.4M | $144.2M | ||
| Q4 24 | $246.6M | $255.0M | ||
| Q3 24 | $250.7M | $346.8M | ||
| Q2 24 | $240.3M | $432.4M |
总资产CLBRARE
| Q1 26 | $587.7M | — | ||
| Q4 25 | $584.0M | $1.5B | ||
| Q3 25 | $591.4M | $1.2B | ||
| Q2 25 | $602.1M | $1.3B | ||
| Q1 25 | $591.5M | $1.3B | ||
| Q4 24 | $585.1M | $1.5B | ||
| Q3 24 | $600.5M | $1.5B | ||
| Q2 24 | $597.8M | $1.6B |
负债/权益比CLBRARE
| Q1 26 | — | — | ||
| Q4 25 | 0.41× | — | ||
| Q3 25 | 0.42× | — | ||
| Q2 25 | 0.48× | — | ||
| Q1 25 | 0.49× | — | ||
| Q4 24 | 0.51× | — | ||
| Q3 24 | 0.56× | — | ||
| Q2 24 | 0.61× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $4.0M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $517.0K | $-100.8M |
| 自由现金流率自由现金流/营收 | 0.4% | -48.6% |
| 资本支出强度资本支出/营收 | — | 0.5% |
| 现金转化率经营现金流/净利润 | 0.77× | — |
| 过去12个月自由现金流最近4个季度 | $22.5M | $-472.0M |
8季度趋势，按日历期对齐
经营现金流CLBRARE
| Q1 26 | $4.0M | — | ||
| Q4 25 | $7.9M | $-99.8M | ||
| Q3 25 | $8.5M | $-91.4M | ||
| Q2 25 | $13.9M | $-108.3M | ||
| Q1 25 | $6.7M | $-166.5M | ||
| Q4 24 | $20.6M | $-79.3M | ||
| Q3 24 | $13.1M | $-67.0M | ||
| Q2 24 | $17.1M | $-77.0M |
自由现金流CLBRARE
| Q1 26 | $517.0K | — | ||
| Q4 25 | $5.0M | $-100.8M | ||
| Q3 25 | $6.5M | $-92.7M | ||
| Q2 25 | $10.4M | $-110.7M | ||
| Q1 25 | $3.9M | $-167.8M | ||
| Q4 24 | $17.4M | $-79.5M | ||
| Q3 24 | $10.4M | $-68.6M | ||
| Q2 24 | $14.3M | $-79.0M |
自由现金流率CLBRARE
| Q1 26 | 0.4% | — | ||
| Q4 25 | 3.6% | -48.6% | ||
| Q3 25 | 4.8% | -58.0% | ||
| Q2 25 | 8.0% | -66.5% | ||
| Q1 25 | 3.1% | -120.5% | ||
| Q4 24 | 13.4% | -48.3% | ||
| Q3 24 | 7.7% | -49.2% | ||
| Q2 24 | 10.9% | -53.7% |
资本支出强度CLBRARE
| Q1 26 | — | — | ||
| Q4 25 | 2.1% | 0.5% | ||
| Q3 25 | 1.5% | 0.8% | ||
| Q2 25 | 2.7% | 1.5% | ||
| Q1 25 | 2.3% | 1.0% | ||
| Q4 24 | 2.5% | 0.1% | ||
| Q3 24 | 2.0% | 1.2% | ||
| Q2 24 | 2.2% | 1.4% |
现金转化率CLBRARE
| Q1 26 | 0.77× | — | ||
| Q4 25 | 1.61× | — | ||
| Q3 25 | 0.60× | — | ||
| Q2 25 | 1.31× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 2.78× | — | ||
| Q3 24 | 1.12× | — | ||
| Q2 24 | 1.90× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CLB
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
